Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to
medications is a critical barrier for the clinician to consistently provide highly effective
IOP-based treatments. Current trial-and error approaches to glaucoma management are
inefficient and have not addressed this barrier as there are no predictive factors for drug
response. Our long-term goal is to improve outcomes by identifying biomarkers and
environmental factors that profile a patient at risk for glaucoma by age-of-onset, rate of
disease progression, "poor response" to treatment, and large IOP fluctuation. Our purpose of
this research project is to address this critical barrier by focusing on physiological
factors that predict IOP response to drugs.
Phase:
Phase 4
Details
Lead Sponsor:
University of Michigan
Collaborators:
Mayo Clinic National Eye Institute (NEI) University of Nebraska